466 related articles for article (PubMed ID: 27223080)
21. Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours.
Chen L; Esfandiari A; Reaves W; Vu A; Hogarty MD; Lunec J; Tweddle DA
Int J Oncol; 2018 Mar; 52(3):967-977. PubMed ID: 29393340
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
[TBL] [Abstract][Full Text] [Related]
24. Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.
Koster R; Timmer-Bosscha H; Bischoff R; Gietema JA; de Jong S
Cell Death Dis; 2011 Apr; 2(4):e148. PubMed ID: 21509038
[TBL] [Abstract][Full Text] [Related]
25. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
26. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.
Ding Q; Zhang Z; Liu JJ; Jiang N; Zhang J; Ross TM; Chu XJ; Bartkovitz D; Podlaski F; Janson C; Tovar C; Filipovic ZM; Higgins B; Glenn K; Packman K; Vassilev LT; Graves B
J Med Chem; 2013 Jul; 56(14):5979-83. PubMed ID: 23808545
[TBL] [Abstract][Full Text] [Related]
27. Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3.
Yang P; Chen W; Li X; Eilers G; He Q; Liu L; Wu Y; Wu Y; Yu W; Fletcher JA; Ou WB
Oncotarget; 2016 May; 7(22):32652-63. PubMed ID: 27129163
[TBL] [Abstract][Full Text] [Related]
28. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
[TBL] [Abstract][Full Text] [Related]
29. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
[TBL] [Abstract][Full Text] [Related]
30. Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas.
Laroche-Clary A; Chaire V; Algeo MP; Derieppe MA; Loarer FL; Italiano A
J Hematol Oncol; 2017 Jun; 10(1):123. PubMed ID: 28629371
[TBL] [Abstract][Full Text] [Related]
31. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
Cheok CF; Dey A; Lane DP
Mol Cancer Res; 2007 Nov; 5(11):1133-45. PubMed ID: 18025259
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells.
Rigatti MJ; Verma R; Belinsky GS; Rosenberg DW; Giardina C
Mol Carcinog; 2012 May; 51(5):363-78. PubMed ID: 21557332
[TBL] [Abstract][Full Text] [Related]
33. Nutlin-3a is a potential therapeutic for ewing sarcoma.
Pishas KI; Al-Ejeh F; Zinonos I; Kumar R; Evdokiou A; Brown MP; Callen DF; Neilsen PM
Clin Cancer Res; 2011 Feb; 17(3):494-504. PubMed ID: 21098696
[TBL] [Abstract][Full Text] [Related]
34. The combination of Nutlin-3 and Tanshinone IIA promotes synergistic cytotoxicity in acute leukemic cells expressing wild-type p53 by co-regulating MDM2-P53 and the AKT/mTOR pathway.
Guo Y; Li Y; Wang FF; Xiang B; Huang XO; Ma HB; Gong YP
Int J Biochem Cell Biol; 2019 Jan; 106():8-20. PubMed ID: 30389549
[TBL] [Abstract][Full Text] [Related]
35. Nutlin-3, an Antagonist of MDM2, Enhances the Radiosensitivity of Esophageal Squamous Cancer with Wild-Type p53.
He T; Guo J; Song H; Zhu H; Di X; Min H; Wang Y; Chen G; Dai W; Ma J; Sun X; Ma J
Pathol Oncol Res; 2018 Jan; 24(1):75-81. PubMed ID: 28341911
[TBL] [Abstract][Full Text] [Related]
36. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.
Gamble LD; Kees UR; Tweddle DA; Lunec J
Oncogene; 2012 Feb; 31(6):752-63. PubMed ID: 21725357
[TBL] [Abstract][Full Text] [Related]
37. MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines.
Ohnstad HO; Paulsen EB; Noordhuis P; Berg M; Lothe RA; Vassilev LT; Myklebost O
BMC Cancer; 2011 May; 11():211:1-11. PubMed ID: 21624110
[TBL] [Abstract][Full Text] [Related]
38. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma.
Van Maerken T; Speleman F; Vermeulen J; Lambertz I; De Clercq S; De Smet E; Yigit N; Coppens V; Philippé J; De Paepe A; Marine JC; Vandesompele J
Cancer Res; 2006 Oct; 66(19):9646-55. PubMed ID: 17018622
[TBL] [Abstract][Full Text] [Related]
39. MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma.
Tabe Y; Sebasigari D; Jin L; Rudelius M; Davies-Hill T; Miyake K; Miida T; Pittaluga S; Raffeld M
Clin Cancer Res; 2009 Feb; 15(3):933-42. PubMed ID: 19188164
[TBL] [Abstract][Full Text] [Related]
40. Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas.
Crane EK; Kwan SY; Izaguirre DI; Tsang YT; Mullany LK; Zu Z; Richards JS; Gershenson DM; Wong KK
PLoS One; 2015; 10(8):e0135101. PubMed ID: 26248031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
